Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, delivering $31.50 in cash per Catalyst share and resulting in CPRX being delisted. The deal is financed by Blackstone (€1B in preferred equity) and CDP Equity (~€1B for a 23.5% Angelini stake), underscoring strong cross-border support for Angelini’s US expansion into Brain Health and Rare Diseases. The transaction solidifies Angelini’s global platform while keeping Italy as a strategic research hub.
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $31.50 per share, totaling around $4.1 billion. This transaction strengthens Angelini's position in the U.S. market for rare diseases, with expected closure in Q3 2026, providing immediate value for Catalyst shareholders.
- CPRX reported adjusted earnings of 38 cents per share, surpassing estimates. - Total revenues were $98.5 million, driven by product sales including Firdapse and Fycompa. - Year to date, Catalyst shares have fallen 12.4% compared to the industry's decline. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- CPRX expected to deliver increase in earnings and revenues in March 2024 quarter. - Earnings report on May 8, 2024 could impact stock price based on results. - Zacks Consensus Estimate for Q1 2024: EPS $0.34, Revenues $97.24 million. - Catalyst's Earnings ESP is +1.19%, Zacks Rank #3, indicating likely beat. - The company beat consensus EPS estimates in two of the last four quarters. Price Impact Rating: bullish Impact Horizon Rating: short-term Type: Research Analysis
